X-ZELL Inc. launches new biotech blog
According to X-ZELL CEO, Dr Sebastian Bhakdi, the blog will allow the company’s extended network of industry experts to reflect and comment on industry trends, and put the company’s pioneering cancer detection work into a broader context.
“When you break new ground in a field as complex and controversial as early cancer detection, education and context are key,” he commented.
“At X-ZELL, we are taking our role as an industry leader very seriously, so we want to contribute to making our ideas accessible to the broadest possible audience – both in the medical and public space.”
Dr Bhakdi explained the monthly blog will feature both text and video elements in the future, adding he would like to see it fuel an “open-minded, objective discussion” about early cancer detection and liquid biopsies.
“X-ZELL is making rapid advances in the field, so it made sense to create an outlet to expand on our ideas and share our vision with the world.
“The overwhelming feedback we received at today’s HealthInvestor Asia Summit is proof that there is a strong appetite for information that goes beyond what you can find in a pitch deck or a media release.”
The blog is live now and can be reached via www.x-zell.com/blog
Established in 2009 with investment from Vichit Suraphongchai – one of the leading figures in Southeast Asian banking – and material support from Thailand’s premier science university, Mahidol University, X-ZELL Inc. started out as a classic university spin-off.
It is the brainchild of Dr Sebastian Chakrit Punyaratabandhu Bhakdi, a German-Thai physician who was working in Bangkok on a fellowship from the German Research Foundation (GFR) when he came across a new way of magnetically separating malaria cells from a blood sample. Upon conclusion of his research, Dr Bhakdi continued to refine the technology and successfully applied it to cancer cell detection, which eventually led to the creation of X-ZELL Inc. The young company’s international breakthrough then came at Y Combinator’s W15 Winter Batch in early 2016, where it showcased a new way of reliably detecting ultra-rare CEC at an early stage – allowing physicians to diagnose malign cancer when it is still treatable. X-ZELL Inc. completed the program with a rare Honourable Mention and seed investment by various Silicon Valley-based angel investors, among them US start-up guru, Paul Buchheit – the creator and lead developer of Gmail. After returning to Bangkok, Dr Bhakdi fast-tracked the company’s corporate evolution with the opening of X-ZELL Inc.’s first overseas office in Sunnyvale, California, and the recruitment of key investor and COO, Johannes Hille, in early 2017. Since then, the company has launched myriad research projects and successfully brought its first commercial cancer test, X-ZELL Prostate™, to market in the Kingdom of Thailand.